UK – NICE issues final guidance on NHS use of Bayer’s Vitrakvi

The National Institute for Health and Care Excellence (NICE) has published final guidance recommending NHS use of Bayer's Vitrakvi (larotrectinib) for a variety of cancers.

The drug is a histology independent cancer treatment that targets all solid tumours with a certain genetic mutation (the NTRK gene fusion), regardless of where the primary tumour is in the body.

NICE has approved NHS funding for the drug via the Cancer Drugs Fund (CDF) as an option for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children if the disease is locally advanced or metastatic or surgery could cause severe health problems and they have no satisfactory treatment options…